備鎮心注射液

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

DIPYRIDAMOLE

可用日期:

裕利股份有限公司 台北市松山區南京東路四段126號10樓，10樓之1-3 (22853066)

ATC代码:

B01AC07

药物剂型:

注射劑

组成:

主成分 () ; DIPYRIDAMOLE (2412400400) MG

每包单位数:

安瓿;;盒裝

类:

製　劑

处方类型:

限由醫師使用

厂商:

BOEHRINGER INGELHEIM ESPANA S.A. FOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH PRAT DE LA RIBA, 50 08174 SANT CUGAT DEL VALLES (BARCELONA), SPAIN ES

治疗领域:

dipyridamole

疗效迹象:

取代心肌造影時所需之運動試驗。

產品總結:

有效日期: 2027/02/19; 英文品名: PERSANTIN INJECTION 10MG/2ML

授权日期:

2002-02-19

资料单张

Druckfarben
Datum/Signatur
KORREKTUR ERBETEN
DRUCKFREIGABE
Auftrags-Nr.
21/0
erstellt
10.03.21
WO
Produktbezeichnung
PERSANTIN INJECTION
10MG/2ML
TW
Maße in mm
155 X 250
PACKAGE INFORM.
PRXX
Artikel-Nr.
921216GI-01
CODE 134
Druckfarben
PANTONE BLACK C
PANTONE 485 C
kleinste Schriftgröße
6,25 PT
SEITE 1
921216GI-01
xxx
1
COMPOSITION
1 ampoule of 2 mL contains
10 mg
2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido(5,4-d)-pyrimidine
(= dipyridamole)
Excipients: tartaric acid, macrogol 600, hydrochloric acid,
water for injection
PHARMACOLOGICAL PROPERTIES
Dipyridamole inhibits the uptake of adenosine into erythrocytes,
platelets and endothelial cells in vitro and in vivo; the inhibition
amounts to 80% at its maximum and occurs dose-dependently at
concentrations of 0.5 - 2 µg/mL. Consequently, there is an increased
concentration of adenosine locally to act on the platelet A2-receptor,
stimulating platelet adenylate cyclase, thereby increasing platelet
cAMP
levels. Thus, platelet aggregation in response to various stimuli such
as
PAF, collagen and ADP is inhibited. Reduced platelet aggregation
reduces
platelet consumption towards normal levels. In addition, adenosine has
a
vasodilator effect and this is one of the mechanisms by which
dipyridamole produces vasodilation.
Presumably via a ‘steal effect’ the vasodilation induced by
PERSANTIN
administered i.v. in doses used for cardiac imaging techniques leads
to
regional redistribution of coronary blood flow and may lead to
abnormalities in thallium distribution and ventricular function in
patients
with coronary artery disease. The normal vessels dilate with enhanced
flow, leaving relatively reduced pressure and flow across areas of
haemodynamically important coronary stenoses.
Dipyridamole inhibits phosphodiesterase (PDE) in various tissues.
Whilst the inhibition of cAMP-PDE is weak, therapeutic levels inhibit
cGMP-PDE, thereby augmenting the increase in cGMP produced by EDRF
(endothelium-derived relaxing factor, identified as NO).
Dipyridamole also stimulates th